Kidney Cancer News and Latest Research
- Positive margins after minimally invasive partial/radical nephrectomy tied to higher local recurrence Retrospective · Eur Urol Focus · 2026-11-18
In a cohort of 3812 patients with localized RCC, positive surgical margins after minimally invasive surgery were associated with markedly higher local recurrence (SHR 5.95) and atypical recurrence (SHR 9.02), an interaction not seen with open surgery.
Why it matters: Raises the question of whether margin status after minimally invasive nephrectomy warrants closer surveillance, hypothesis generating from a single retrospective cohort.
- New MAGNIS score refines risk stratification for adjuvant pembrolizumab eligibility in ccRCC Retrospective · Urol Oncol · 2026-11-18
In 402 KEYNOTE-564-eligible patients, an integer-based score (tumor necrosis, age, M1NED, IVC thrombus, grade, pT4/pN+) stratified 4-year disease-free survival with moderate discrimination (C-index 67.8%).
Why it matters: Raises the question of whether a simple risk score could help individualize adjuvant pembrolizumab decisions, pending external validation.
- Meta-analysis finds checkpoint inhibitor combos benefit poor-risk ccRCC patients most Meta-analysis · Eur Urol · 2026-11-17
Pooling individual and aggregate data from four first-line immunotherapy trials in metastatic clear-cell RCC, survival benefit over sunitinib was concentrated in IMDC/CPI2 poor-risk patients (HR 0.51) with minimal benefit in favorable-risk patients (HR 0.98).
Why it matters: Suggests prognostic risk group may help identify which patients derive the most survival benefit from first-line IO combinations.
- CHMP recommends EU approval of belzutifan plus lenvatinib for advanced ccRCC Intl regulatory · Urology Times · 2026-11-13
The European Medicines Agency's CHMP has issued a positive opinion recommending approval of belzutifan combined with lenvatinib for advanced clear cell renal cell carcinoma.
Why it matters: If ratified by the European Commission, this would add a new combination option for advanced ccRCC in Europe.
- Robotic IVC thrombectomy linked to less blood loss and fewer complications than open surgery Retrospective · BJU Int · 2026-11-14
In a single-center retrospective cohort of 226 patients with renal tumor IVC thrombi (Mayo I-IV), robot-assisted thrombectomy was associated with less blood loss, shorter stay, fewer transfusions and complications than open surgery, with similar survival after adjustment and propensity matching.
Why it matters: Suggests robotic IVC thrombectomy may offer perioperative advantages over open surgery at experienced centers, without apparent oncologic tradeoff, though data are retrospective and single-center.
- Liver transplant team involvement tied to fewer complications in high-level IVC thrombectomy Retrospective · Urol Oncol · 2026-11-14
In a 36-patient single-center cohort of level III/IV renal tumor thrombectomy, cases with liver transplant team involvement had fewer major complications (11% vs 50%) and less hepatic dysfunction (0% vs 39%), but associations were attenuated and lost significance after adjusting for year of surgery.
Why it matters: Hypothesis generating only; in this small single center series the signal weakened after adjusting for year of surgery, so a causal benefit is unproven.
- Chinese expert consensus standardizes technique for robot-assisted partial nephrectomy Guideline · Transl Androl Urol · 2026-11-08
A Chinese expert consensus, developed via a three-round Delphi process with GRADE-ADOLOPMENT methodology, addresses ten key clinical questions on patient selection, indications, contraindications, and operative approach (including transperitoneal vs retroperitoneal access) for robot-assisted partial nephrectomy, including expanded use for hilar, endophytic, and complex renal tumors.
Why it matters: Offers a standardized framework from Chinese experts that may inform practice as robotic partial nephrectomy indications expand to more complex tumors.
- Meta-analysis: elevated neutrophil-to-lymphocyte ratio linked to worse survival in RCC Meta-analysis · Transl Androl Urol · 2026-11-08
An updated meta-analysis of 26 cohort studies (6,041 patients) found elevated neutrophil-to-lymphocyte ratio associated with shorter overall, recurrence-free, and disease-free survival in renal cell carcinoma.
Why it matters: Adds support for NLR as a prognostic marker in RCC, though pooled cohort data cannot establish causality or guide individual treatment decisions.
- CD70-targeted PET/CT shows higher sensitivity than PSMA PET for clear cell RCC metastases Prospective · Clin Cancer Res · 2026-11-07
In a retrospective cohort of 128 patients and a prospective head-to-head study of 36 patients, CD70-targeted PET/CT ([68Ga]Ga-NOTA-RCCB6) showed higher sensitivity than PSMA PET ([68Ga]Ga-PSMA-11) for clear cell RCC (88.7% vs 76.1%, P<0.001), especially for lung and liver metastases. Among 26 evaluable patients, CD70 imaging improved lesion detection extent in 35% and changed treatment decisions in 15%.
Why it matters: New imaging data suggest CD70-targeted PET/CT may outperform PSMA PET for detecting clear cell RCC metastases, but findings come from a mixed retrospective/small prospective design and need larger validation.
- Updated prognostic index for renal cell carcinoma brain metastases shows longer survival in contemporary era Retrospective · Lancet Oncol · 2026-11-06
In a 21-institution cohort of 1049 patients with newly diagnosed RCC brain metastases (2016-2022), median overall survival was 20.0 months, roughly double the 9.6 and 12.0 months seen in legacy cohorts from 1985-2015; an updated Renal GPA incorporated performance status, albumin, number of brain metastases, and extracranial disease.
Why it matters: Provides a contemporary, multi-institution benchmark and updated prognostic tool for counseling and trial stratification in RCC patients with brain metastases.
Urology clinical trials · Urology podcasts · Urology videos · Meetings · Daily edition archive
Loading today's edition…